Quantbot Technologies LP Makes New $1.26 Million Investment in Dr. Reddy's Laboratories Ltd $RDY

Key Points

• Quantbot Technologies LP has acquired a new position in Dr. Reddy's Laboratories Ltd, purchasing 95,263 shares valued at approximately $1.26 million in the first quarter.
• Several institutional investors, including Brooklyn Investment Group and American Century Companies Inc., have significantly increased their holdings in Dr. Reddy's during the same period.
• Dr. Reddy's Laboratories reported better-than-expected quarterly earnings, with an EPS of $0.20 beating estimates, and analysts forecast a 0.8 EPS for the current fiscal year.

Quantbot Technologies LP acquired a new position in Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 95,263 shares of the company's stock, valued at approximately $1,257,000.

A number of other large investors have also modified their holdings of RDY. Brooklyn Investment Group raised its position in shares of Dr. Reddy's Laboratories by 491.9% during the 1st quarter. Brooklyn Investment Group now owns 6,393 shares of the company's stock worth $84,000 after purchasing an additional 5,313 shares during the last quarter. Corient IA LLC acquired a new position in shares of Dr. Reddy's Laboratories during the 1st quarter worth about $330,000. American Century Companies Inc. raised its position in shares of Dr. Reddy's Laboratories by 6.0% during the 1st quarter. American Century Companies Inc. now owns 914,473 shares of the company's stock worth $12,062,000 after purchasing an additional 52,108 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Dr. Reddy's Laboratories during the 1st quarter worth about $143,000. Finally, Vestmark Advisory Solutions Inc. raised its position in shares of Dr. Reddy's Laboratories by 127.2% during the 1st quarter. Vestmark Advisory Solutions Inc. now owns 36,180 shares of the company's stock worth $477,000 after purchasing an additional 20,258 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Up 0.7%

RDY stock opened at $14.5150 on Friday. The company has a market cap of $12.12 billion, a price-to-earnings ratio of 21.99, a PEG ratio of 5.81 and a beta of 0.29. The company has a current ratio of 1.89, a quick ratio of 1.36 and a debt-to-equity ratio of 0.01. Dr. Reddy's Laboratories Ltd has a 12 month low of $12.26 and a 12 month high of $16.77. The firm has a 50-day moving average of $14.60 and a two-hundred day moving average of $14.03.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.02. The company had revenue of $988.82 million during the quarter, compared to the consensus estimate of $88.27 billion. Dr. Reddy's Laboratories had a net margin of 16.99% and a return on equity of 17.25%. As a group, analysts forecast that Dr. Reddy's Laboratories Ltd will post 0.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

RDY has been the subject of several research analyst reports. Zacks Research upgraded shares of Dr. Reddy's Laboratories from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Wall Street Zen upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. HSBC upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and upped their price target for the stock from $14.44 to $16.90 in a research report on Thursday, June 5th. Finally, Hsbc Global Res upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.95.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.